The Prediction Model of High-Frequency Ultrasound Combined with Artificial Intelligence-Assisted Scoring System Improved the Diagnosis of Sclerosing Adenosis and Early Breast Cancer

被引：1
作者：
Ma, Bingxin [1 ]
Wu, Gang [1 ]
Zhu, Haohui [1 ]
Liu, Yifei [1 ]
Hu, Wenjia [1 ]
Zhao, Jing [1 ]
Liu, Yinlong [1 ]
Liu, Qiuyu [2 ]
机构：
[1] Henan Prov Peoples Hosp, Dept Ultrasound, Zhengzhou 450000, Peoples R China
[2] Henan Prov Peoples Hosp, Dept Pathol, Zhengzhou 450000, Peoples R China
来源：
BREAST CANCER-TARGETS AND THERAPY | 2025年 / 17卷
关键词：
sclerosing adenosis; breast tumor; ultrasound; AI; computer-aided diagnosis; DUCTAL CARCINOMA;
D O I：
10.2147/BCTT.S483496
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Objective: The study aimed to apply an artificial intelligence (AI)-assisted scoring system, and improve the diagnostic efficiency of Sclerosing adenosis and early breast cancer. Methods: This study retrospectively collected adenopathy patients (156 cases) and early breast cancer patients (150 cases) in Henan Provincial People's Hospital from August 2020 to April 2023. Results: The area under the curve of the model constructed by clinical ultrasound features and combined AI features to predict and identify the two in the training group was 0.89 and 0.94, respectively. The combined AI model with the best performance (training AUC, 0.94, 95% CI, 0.91-0.97 and validation AUC, 0.95, 95% CI, 0.90-0.99) was superior to the clinical ultrasound feature model, and the decision curve also showed that the clinical ultrasound combined with AI Nomogram had good clinical practicability. In the training group, the AUC of the sonographer and AI in differential diagnosis was 0.67(95% CI, 0.62-0.71) and 0.89(95% CI, 0.84-0.93), respectively, and the sonographer's assessment showed better sensitivity (1.00 VS 0.73), but AI showed a higher accuracy Conclusion: Age, lesion size, burr, blood flow, and AI risk score are independent predictors of sclerosing adenosis and early breast cancer. The combined clinical ultrasound feature and AI model are correlated with AI risk score, US routine features, and clinical data, superior to the clinical ultrasound model and BI-BADS grading, and have good diagnostic performance, which can provide clinicians with a more effective diagnostic tool.
引用
收藏
页码：145 / 155
页数：11
相关论文
共 24 条
  • [1] Visscher DW, Nasser A, Degnim AC, Et al., Sclerosing adenosis and risk of breast cancer, Breast Cancer Res Treat, 144, 1, pp. 205-212, (2014)
  • [2] Yoshida A, Hayashi N, Akiyama F, Et al., Ductal carcinoma in situ that involves sclerosing adenosis: high frequency of bilateral breast cancer occurrence, Clin Breast Cancer, 12, 6, pp. 398-403, (2012)
  • [3] Chen YL, Chen JJ, Chang C, Et al., Sclerosing adenosis: ultrasonographic and mammographic findings and correlation with histopathology, Mol Clin Oncol, 6, 2, pp. 157-162, (2017)
  • [4] Guirguis MS, Adrada B, Santiago L, Candelaria R, Arribas E., Mimickers of breast Malignancy: imaging findings, pathologic concordance and clinical management, Insights Imaging, 12, 1, (2021)
  • [5] Huang N, Chen J, Xue J, Et al., Breast sclerosing adenosis and accompanying Malignancies: a clinicopathological and imaging study in a Chinese population, Medicine, 94, 49, (2015)
  • [6] Bacci J, MacGrogan G, Alran L, Labrot-Hurtevent G., Management of radial scars/complex sclerosing lesions of the breast diagnosed on vacuum-assisted large-core biopsy: is surgery always necessary?, Histopathol, 75, pp. 900-915, (2019)
  • [7] Leibig C, Brehmer M, Bunk S, Et al., Combining the strengths of radiologists and AI for breast cancer screening: a retrospective analysis, Lancet Digit Health, 4, 7, pp. e507-e519, (2022)
  • [8] Pfob A, Sidey-Gibbons C, Barr RG, Et al., The importance of multi-modal imaging and clinical information for humans and AI-based algorithms to classify breast masses (INSPiRED 003): an international, multicenter analysis, Eur Radiol, 32, 6, pp. 4101-4115, (2022)
  • [9] Tan H, Zhang H, Lei Z, Fu F, Wang M., Radiological and clinical findings in sclerosing adenosis of the breast, Medicine, 98, 39, (2019)
  • [10] Gradishar WJ, Moran MS, Abraham J, Et al., Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology, J Natl Compr Cancer Netw, 20, 6, pp. 691-722, (2022)
123